In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically 'undruggable' protein, in just two months. This ...

RiDYMO® has been successfully employed in various drug discovery programs, including the development of small molecule ...

You love to see it. With such a gluttony of choice, it became harder than ever for PC hardware and software to impress us. Few products earned our rare Editors’ Choice award. And only the very ...